RU2012134041A - Способ лечения воспалительного заболевания и расстройства - Google Patents
Способ лечения воспалительного заболевания и расстройства Download PDFInfo
- Publication number
- RU2012134041A RU2012134041A RU2012134041/15A RU2012134041A RU2012134041A RU 2012134041 A RU2012134041 A RU 2012134041A RU 2012134041/15 A RU2012134041/15 A RU 2012134041/15A RU 2012134041 A RU2012134041 A RU 2012134041A RU 2012134041 A RU2012134041 A RU 2012134041A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- seq
- administered
- kit
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 53
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract 36
- 229920001184 polypeptide Polymers 0.000 claims abstract 141
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 141
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 141
- 239000003112 inhibitor Substances 0.000 claims abstract 31
- 238000011191 terminal modification Methods 0.000 claims abstract 26
- 150000003839 salts Chemical class 0.000 claims abstract 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 22
- 210000004899 c-terminal region Anatomy 0.000 claims abstract 13
- 230000003442 weekly effect Effects 0.000 claims abstract 13
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 claims abstract 10
- 102100024924 Protein kinase C alpha type Human genes 0.000 claims abstract 10
- 230000002757 inflammatory effect Effects 0.000 claims abstract 9
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 9
- 210000004877 mucosa Anatomy 0.000 claims abstract 7
- 230000002685 pulmonary effect Effects 0.000 claims abstract 7
- 206010012442 Dermatitis contact Diseases 0.000 claims abstract 6
- 150000001413 amino acids Chemical class 0.000 claims abstract 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 3
- 208000011231 Crohn disease Diseases 0.000 claims abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 3
- 201000004681 Psoriasis Diseases 0.000 claims abstract 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims abstract 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 3
- 206010046851 Uveitis Diseases 0.000 claims abstract 3
- 208000002029 allergic contact dermatitis Diseases 0.000 claims abstract 3
- 208000006673 asthma Diseases 0.000 claims abstract 3
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract 3
- 208000010247 contact dermatitis Diseases 0.000 claims abstract 3
- 206010023332 keratitis Diseases 0.000 claims abstract 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims abstract 3
- 206010028417 myasthenia gravis Diseases 0.000 claims abstract 3
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims abstract 2
- 231100000853 glomerular lesion Toxicity 0.000 claims abstract 2
- 239000012190 activator Substances 0.000 claims 12
- 208000003251 Pruritus Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 108090000315 Protein Kinase C Proteins 0.000 claims 7
- 230000006378 damage Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 231100000234 hepatic damage Toxicity 0.000 claims 2
- 201000006334 interstitial nephritis Diseases 0.000 claims 2
- 230000008818 liver damage Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11013—Protein kinase C (2.7.11.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29379410P | 2010-01-11 | 2010-01-11 | |
| US61/293,794 | 2010-01-11 | ||
| US40550910P | 2010-10-21 | 2010-10-21 | |
| US61/405,509 | 2010-10-21 | ||
| PCT/IL2011/000032 WO2011083481A2 (en) | 2010-01-11 | 2011-01-11 | Method for treatment of inflammatory disease and disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012134041A true RU2012134041A (ru) | 2014-02-20 |
Family
ID=44305895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134041/15A RU2012134041A (ru) | 2010-01-11 | 2011-01-11 | Способ лечения воспалительного заболевания и расстройства |
| RU2012133148/15A RU2012133148A (ru) | 2010-01-11 | 2011-01-11 | Способ лечения воспалительного заболевания и расстройства |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012133148/15A RU2012133148A (ru) | 2010-01-11 | 2011-01-11 | Способ лечения воспалительного заболевания и расстройства |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8349793B2 (enExample) |
| EP (3) | EP2523677A2 (enExample) |
| JP (2) | JP2013516500A (enExample) |
| CN (2) | CN103083669A (enExample) |
| AU (1) | AU2011204425A1 (enExample) |
| CA (2) | CA2789972A1 (enExample) |
| RU (2) | RU2012134041A (enExample) |
| WO (3) | WO2011083481A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2535029C (en) | 2003-08-07 | 2013-07-16 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| US8367606B2 (en) | 2005-08-29 | 2013-02-05 | Healor Ltd. | Method and compositions for prevention and treatment of diabetic and aged skin |
| RU2013117209A (ru) * | 2010-11-08 | 2014-10-27 | Хилор Лтд. | Буферные глазные композиции и способы их применения |
| WO2014041537A1 (en) * | 2012-09-13 | 2014-03-20 | Healor Ltd. | Protein kinase c (pkc) alpha inhibitors for treatment and prevention of toxicities caused by radiation |
| US20160075753A1 (en) | 2013-04-30 | 2016-03-17 | La Jolla Institute For Allergy And Immunology | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-eta |
| JP2017520531A (ja) | 2014-06-02 | 2017-07-27 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | Ｆｃ断片の産生 |
| US10328114B2 (en) * | 2014-10-28 | 2019-06-25 | University Of Iowa Research Foundation | Lung injury repair compositions and methods |
| WO2019116096A1 (en) | 2017-12-15 | 2019-06-20 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Production of fc fragments |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549747A (en) | 1968-02-20 | 1970-12-22 | Flow Pharma Inc | Contact lens wetting solution and method of using same |
| US3947573A (en) | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
| US3856919A (en) | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767788A (en) | 1970-06-08 | 1973-10-23 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767789A (en) | 1971-06-21 | 1973-10-23 | Burton Parsons & Co Inc | Method of providing a synthetic mucus in vivo |
| US3987163A (en) | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
| US3907985A (en) | 1973-07-27 | 1975-09-23 | Burton Parsons And Company Inc | Polystyrene sulfonate containing opthalmic solutions |
| US4029817A (en) | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
| US3920810A (en) | 1974-04-23 | 1975-11-18 | Burton Parsons And Company Inc | Polyacrylamide containing ophthalmic solutions |
| US4120949A (en) | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4558033A (en) | 1983-06-06 | 1985-12-10 | Amgen | Potentiation of the effects of insulin by peptides |
| US4673649A (en) | 1983-07-15 | 1987-06-16 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
| WO1985005036A1 (en) | 1984-04-30 | 1985-11-21 | The Trustees Of Columbia University In The City Of | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch |
| EP0223977B1 (en) | 1985-11-25 | 1990-10-10 | Wako Pure Chemical Industries, Ltd. | Colour developing method in clinical examinations |
| US4833257A (en) | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| JPH0739508B2 (ja) | 1986-11-11 | 1995-05-01 | 株式会社林原生物化学研究所 | プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途 |
| US4885163A (en) | 1987-02-24 | 1989-12-05 | Eli Lilly And Company | Topical use of IGF-II for wound healing |
| US4808402A (en) | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
| JPS63303929A (ja) | 1987-06-04 | 1988-12-12 | Kanji Izumi | 創傷治療剤 |
| US5700450A (en) | 1988-03-30 | 1997-12-23 | The Trustees Of Boston University | Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof |
| ZA892928B (en) | 1988-04-25 | 1991-01-30 | Pro Neuron Inc | Pharmaceutical compositions containing deoxyribonucleosides for wound healing |
| US5137734A (en) | 1989-03-22 | 1992-08-11 | Dana Farber Cancer Institute | Angiogenic monoglycerides |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5158935A (en) | 1989-05-12 | 1992-10-27 | Chiron Corporation | Human epidermal growth factor having substitution at position 11 |
| US5723119A (en) | 1989-07-28 | 1998-03-03 | Schering Corporation | Method for enhancing wound healing/repair with IL-4 |
| US5145679A (en) | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
| US5423778A (en) | 1989-12-14 | 1995-06-13 | Elof Eriksson | System and method for transplantation of cells |
| US5981606A (en) | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
| CZ213693A3 (en) | 1991-04-11 | 1994-05-18 | Schering Corp | Diindolepyrrolbenzodiazocines, process of their preparation and use, and a pharmaceutical mixture based thereon |
| CA2108266C (en) | 1991-04-19 | 2003-06-03 | Albert J. Owen | Convertible microemulsion formulations |
| JPH0543453A (ja) | 1991-08-20 | 1993-02-23 | Sumitomo Pharmaceut Co Ltd | 創傷治癒促進用局所用徐放性製剤 |
| US5591709A (en) | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| HUT67319A (en) | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
| WO1993008825A1 (en) | 1991-11-04 | 1993-05-13 | Zymogenetics, Inc. | Pdgf gel formulation |
| US5948898A (en) * | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
| US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| DE4208552A1 (de) | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | Topische arzneiformen mit insulin |
| GB9210574D0 (en) | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
| CA2125060C (en) | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
| DE69531712T2 (de) | 1994-04-25 | 2004-07-01 | Japan Science And Technology Corp., Kawaguchi | Hybridgel, das eine biologisch aktive Substanz sekretiert |
| US6028118A (en) | 1996-08-08 | 2000-02-22 | Les Laboratoires Aeterna Inc. | Methods of using extracts of shark cartilage |
| JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| RU2198900C2 (ru) | 1994-05-24 | 2003-02-20 | Еда Рисерч энд Дивелопмент Ко., Лтд. | Усовершенствованный сополимер-1 и способ его получения |
| JPH07316066A (ja) | 1994-05-26 | 1995-12-05 | Mochida Pharmaceut Co Ltd | 創傷治癒剤 |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5631245A (en) | 1995-06-06 | 1997-05-20 | Biodynamics Pharmaceuticals, Inc. | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions |
| US6455247B1 (en) | 1996-01-23 | 2002-09-24 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| IL126873A (en) * | 1996-05-30 | 2005-09-25 | Aventis Pharma Inc | Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors |
| US5869037A (en) | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
| JPH10158188A (ja) | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| GB9702943D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
| JPH10265405A (ja) | 1997-03-19 | 1998-10-06 | Masaaki Nanbara | インスリン含有の皮膚外用製剤 |
| US6274712B1 (en) | 1997-12-23 | 2001-08-14 | 3-Dimensional Pharmaceuticals, Inc. | Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137 |
| FR2773075B1 (fr) | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
| DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
| US6489306B2 (en) | 1998-02-23 | 2002-12-03 | University Of South Florida | Method of intranasal gene transfer for protection against respiratory infection |
| US6335201B1 (en) | 1998-03-06 | 2002-01-01 | The Regents Of The University Of California | Method and apparatus for detecting enzymatic activity using molecules that change electrophoretic mobility |
| US6376467B1 (en) | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| US6096288A (en) | 1998-10-12 | 2000-08-01 | Mobil Oil Corporation | Synthesis of the cubic mesoporous molecular sieve MCM-48 |
| WO2000030628A2 (en) | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
| US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
| US6541447B1 (en) | 1999-09-01 | 2003-04-01 | B & M Healthcare Technologies, Inc. | Wound healing composition and method for use thereof |
| EP1259595B1 (en) | 2000-02-25 | 2007-04-04 | Immunex Corporation | Integrin antagonists |
| AU2001245945A1 (en) * | 2000-03-23 | 2001-10-03 | Pe Corporation (Ny) | Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof |
| JP2003530156A (ja) | 2000-04-06 | 2003-10-14 | ユニバーシティ ライセンス ホールディングス インコーポレイテッド | 創傷治癒を促進するための組成物および方法 |
| US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| US20100129332A1 (en) | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
| US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| US20030148924A1 (en) | 2002-07-09 | 2003-08-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions of healing wounds |
| DK1383540T3 (da) | 2000-07-31 | 2009-08-24 | Univ Bar Ilan | Fremgangsmdåer og farmaceutiske sammensætninger til sårheling |
| US6673603B2 (en) | 2000-09-01 | 2004-01-06 | Modex Therapeutiques, S.A. | Cell paste comprising keratinocytes and fibroblasts |
| GB2369572A (en) | 2000-11-29 | 2002-06-05 | Raft Trustees Ltd | Wound treatment composition comprising insulin |
| JP2002198443A (ja) | 2000-12-26 | 2002-07-12 | Nec Corp | 半導体装置及びその製造方法 |
| US20020119914A1 (en) | 2000-12-26 | 2002-08-29 | Deguang Zhu | New uses of insulin and pancreatin |
| GB0103877D0 (en) | 2001-02-16 | 2001-04-04 | King S College London | Novel Drug Delivery system |
| DE10109280A1 (de) * | 2001-02-26 | 2002-09-05 | Peter Mayser | Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen |
| ES2315358T3 (es) | 2001-03-08 | 2009-04-01 | University Of Kentucky Research Foundation | Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico. |
| JP2002272831A (ja) | 2001-03-14 | 2002-09-24 | Fumio Kamiyama | 創傷被覆用粘着性シート |
| WO2002087576A1 (en) | 2001-04-30 | 2002-11-07 | Arachnova Therapeutics Ltd. | The treatment of scarring and related conditions using ppar-gamma activators |
| WO2002094877A2 (en) | 2001-05-23 | 2002-11-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New nuclear receptor cofactors and related modulators |
| ES2184623B1 (es) | 2001-06-29 | 2004-09-16 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (C.I.E.M.A.T.) | Piel artificial autologa secretora de leptina y metodo de obtencion. |
| US20030124503A1 (en) | 2001-12-28 | 2003-07-03 | Olivencia-Yurvati Albert H. | Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof |
| AU2003209226A1 (en) | 2002-01-11 | 2003-07-30 | Michael Tennant | Adiponectin gene therapy |
| RU2249467C2 (ru) | 2002-11-25 | 2005-04-10 | ООО Научно-производственное предприятие "ЭРЛОН", Лтд. | Медицинский материал и изделия на его основе |
| US20040175384A1 (en) | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
| DK1641910T3 (da) * | 2003-07-02 | 2013-05-21 | Verenium Corp | Glucanaser, nucleinsyrer, som koder for disse, og fremgangsmåder til at fremstille og benytte disse |
| EP1646383A4 (en) | 2003-07-21 | 2009-03-25 | Bethesda Pharmaceuticals Inc | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR |
| CA2535029C (en) | 2003-08-07 | 2013-07-16 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| EP1670497A4 (en) | 2003-09-16 | 2009-07-15 | Garvan Inst Med Res | METHOD FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C EPSILON (PKC Ε) AND METHOD FOR TREATING THEREOF CONVERTING DERIVED GLUCOSE METABOLISM |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US20080206270A1 (en) * | 2004-07-08 | 2008-08-28 | Minev Boris R | Enhancing Class I Antigen Presentation With Synthetic Sequences |
| WO2006086681A2 (en) * | 2005-02-09 | 2006-08-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting smooth muscle cell migration and proliferation |
| US8158586B2 (en) * | 2005-04-11 | 2012-04-17 | Pharmagap Inc. | Inhibitors of protein kinases and uses thereof |
| EP1922086A4 (en) * | 2005-08-05 | 2011-08-03 | Pharmagap Inc | TARGETED PROTEIN KINASE C HEMMER AND ITS USES |
| US8367606B2 (en) | 2005-08-29 | 2013-02-05 | Healor Ltd. | Method and compositions for prevention and treatment of diabetic and aged skin |
| US20090306045A1 (en) | 2005-12-22 | 2009-12-10 | Ira Mellman | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease |
| KR20090023722A (ko) * | 2006-06-20 | 2009-03-05 | 메타프로테오믹스, 엘엘씨 | 테트라하이드로이소알파산 기본 단백질 키나제 변조 암 치료방법 |
| NZ582556A (en) * | 2007-07-30 | 2013-02-22 | Healor Ltd | Pharmaceutical composition for treating wounds and related methods |
| WO2009097133A2 (en) * | 2008-01-30 | 2009-08-06 | Monsanto Technology, Llc | Transgenic plants with enhanced agronomic traits |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| KR20130095835A (ko) | 2009-02-24 | 2013-08-28 | 힐로 리미티드 | 여드름 및 기타 질환 치료용 비스파틴 치료제 |
-
2011
- 2011-01-11 EP EP11731747A patent/EP2523677A2/en not_active Withdrawn
- 2011-01-11 CA CA2789972A patent/CA2789972A1/en not_active Abandoned
- 2011-01-11 JP JP2012548532A patent/JP2013516500A/ja not_active Withdrawn
- 2011-01-11 CN CN2012103111308A patent/CN103083669A/zh active Pending
- 2011-01-11 CA CA2786854A patent/CA2786854A1/en not_active Abandoned
- 2011-01-11 EP EP12008309.2A patent/EP2599494A1/en not_active Withdrawn
- 2011-01-11 AU AU2011204425A patent/AU2011204425A1/en not_active Abandoned
- 2011-01-11 WO PCT/IL2011/000032 patent/WO2011083481A2/en not_active Ceased
- 2011-01-11 WO PCT/IL2011/000034 patent/WO2011083483A2/en not_active Ceased
- 2011-01-11 CN CN2011800057108A patent/CN102724994A/zh active Pending
- 2011-01-11 RU RU2012134041/15A patent/RU2012134041A/ru unknown
- 2011-01-11 WO PCT/IL2011/000033 patent/WO2011083482A2/en not_active Ceased
- 2011-01-11 EP EP11731746.1A patent/EP2536421A4/en not_active Withdrawn
- 2011-01-11 RU RU2012133148/15A patent/RU2012133148A/ru unknown
- 2011-07-13 US US13/181,687 patent/US8349793B2/en not_active Expired - Fee Related
-
2012
- 2012-12-10 US US13/709,727 patent/US20130274196A1/en not_active Abandoned
-
2013
- 2013-07-02 JP JP2013139038A patent/JP2013231052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011083483A3 (en) | 2011-11-17 |
| EP2523677A2 (en) | 2012-11-21 |
| WO2011083482A2 (en) | 2011-07-14 |
| WO2011083482A3 (en) | 2012-03-08 |
| AU2011204425A1 (en) | 2012-08-02 |
| WO2011083483A2 (en) | 2011-07-14 |
| CN103083669A (zh) | 2013-05-08 |
| EP2536421A4 (en) | 2013-10-09 |
| CA2789972A1 (en) | 2011-07-14 |
| WO2011083481A3 (en) | 2012-03-22 |
| CA2786854A1 (en) | 2011-07-14 |
| RU2012133148A (ru) | 2014-02-20 |
| WO2011083481A2 (en) | 2011-07-14 |
| EP2536421A2 (en) | 2012-12-26 |
| US20130274196A1 (en) | 2013-10-17 |
| US20120190611A1 (en) | 2012-07-26 |
| CN102724994A (zh) | 2012-10-10 |
| US8349793B2 (en) | 2013-01-08 |
| JP2013231052A (ja) | 2013-11-14 |
| JP2013516500A (ja) | 2013-05-13 |
| EP2599494A1 (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012134041A (ru) | Способ лечения воспалительного заболевания и расстройства | |
| US12478617B2 (en) | Lipidated peptide inhibitors of interleukin-23 receptor | |
| JP5255456B2 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| JP4966659B2 (ja) | 異なる細胞に機能的に影響を及ぼし、免疫性疾患、炎症性疾患、神経疾患、およびその他の疾患を治療するための二重のアラニルアミノペプチダーゼおよびジペプチジルペプチダーゼｉｖの阻害剤 | |
| CA2729938A1 (en) | New insulin analogues of prolonged activity | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2004536077A5 (enExample) | ||
| CA2631647A1 (en) | Use of branched-chain amino acids for the treatment of muscle loss | |
| JP2018504901A (ja) | 安定性が増加されたグルカゴン誘導体 | |
| Yang et al. | Design, synthesis, and evaluation of l-cystine diamides as l-cystine crystallization inhibitors for cystinuria | |
| EP3423468A1 (en) | Aza-peptide aldehydes and ketones | |
| WO2018005527A1 (en) | Liponucleotide-based therapy for ards | |
| EP3701966A1 (en) | Drug and method for treating liver diseases related to hepatitis b viruses in full-dose condition | |
| RU2012134322A (ru) | Органические соединения для регуляции векторных ионных каналов | |
| JP2006503069A5 (enExample) | ||
| JP2008519815A (ja) | 化合物 | |
| AU2007226359A1 (en) | Amino acid derivatives | |
| JP5053665B2 (ja) | 催眠用医薬組成物 | |
| JP7239221B2 (ja) | 炎症性疾患または自己免疫性疾患の予防または治療活性を有するペプチドとその用途 | |
| JPWO2019246225A5 (enExample) | ||
| JP2014523437A (ja) | 癌の予防および治療における効力のある薬剤としての新規亜鉛フィンガー様ペプチド組成物 | |
| US9051350B2 (en) | Macrocyclic antiproliferation agents and methods of treatment | |
| WO2024089159A1 (en) | Main protease inhibitors | |
| RU2014116550A (ru) | Гликозилированный полипептид и содержащая его фармацевтическая композиция | |
| CN102596894B (zh) | 2-氨基-3-甲基-己-5-烯酸及其在制备肽如杆菌肽中的应用 |